GLP-1-based therapies may offer benefits in inflammatory bowel disease (IBD) beyond their metabolic indication beyond weight loss. These findings come from two poster presentations at the Crohn's & Colitis Congress in Las Vegas. GLP-1 therapies reduce inflammation, which is beneficial in IBD. Presentations were made at a large meeting of experts. Studies suggest added value of GLP-1 therapy in IBD beyond weight loss. The results were reported in MedPage Today.